The discovery of the BCR-ABL1 fusion kinase in chronic myeloid leukemia prompted the development of the targeted inhibitor imatinib, the first small molecule signal transduction inhibitor approved for clinical use, which greatly improved long-term survival for patients with chronic myeloid leukemia [16]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.